Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia
Rozzano, Lombardia, Italy
Specialized hospital in Italy
Via Alessandro Manzoni, 56, 20089 Rozzano MI
About Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
19
Gruppo Italiano Malattie EMatologiche dell'Adulto
7
Fondazione Italiana Linfomi ONLUS
3
Ospedale di Circolo - Fondazione Macchi
1
Clinical Trials at Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia
During the past decade, Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 6 clinical trials were completed, i.e. on
average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 4 clinical trials were completed. i.e. 36.4%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
2011-07-06
2021-07-30
Completed
1,401
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)
2011-03-31
2017-01-31
Completed
50
Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia
2012-01-01
2018-07-10
Completed
515
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
2013-07-31
2019-05-28
Completed
159
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
2014-01-31
2021-06-04
Completed
1,846
MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate
2014-05-20
2020-12-07
Completed
204
Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program
2016-03-01
2018-10-03
Completed
264
D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia
2017-05-31
2021-06-01
Unknown status
60
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia"
#1 collaborator was "Chugai" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "Exelixis" with 1 trials as a collaborator, "German Low Grade Lymphoma Study Group" with 1 trials as a collaborator and "Institute of Cancer Research, United Kingdom" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were
collaborators in the rest 5 trials.
Clinical Trials Conditions at Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia
According to Clinical.Site data, the most researched conditions in "Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia" are
"Acute Myeloid Leukemia" (3 trials), "Breast Cancer" (2 trials), "Lymphoma, Non-Hodgkin" (2 trials), "Non-Hodgkin's Lymphoma" (2 trials) and "Acute Lymphoblastic Leukemia" (1 trials). Many other conditions were trialed in "Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia" in a lesser frequency.
Clinical Trials Intervention Types at Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia
Most popular intervention types in "Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia" are "Drug" (24 trials), "Other" (5 trials) and "Procedure" (1 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (8 trials), "Cyclophosphamide" (5 trials), "Doxorubicin" (5 trials), "Placebo" (5 trials) and "Tocilizumab" (5 trials). Other intervention names were less common.
Clinical Trials Genders at Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia
The vast majority of trials in "Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia" are
29 trials for "All" genders and 1 trials for "Male" genders.
Clinical Trials Status at Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia
Currently, there are NaN active trials in "Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia".
undefined are not yet recruiting,
8 are recruiting,
13 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 7 completed trials in Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia,
1 suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, 5 "Phase 1"
clinical trials were conducted, 7 "Phase 2" clinical
trials and 13 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 1 trials that are defined as “Not Applicable".